Sigma-Aldrich acquires Cell Marque to grow antibody portfolio

3 October 2014
mergers-acquisitions-big

USA-based life sciences company Sigma-Aldrich (Nasdaq: SIAL) has entered into an agreement to acquire US antibody company Cell Marque in a move to strengthen its antibody portfolio.

Sigma-Aldrich expects this acquisition to be neutral to mildly accretive to earnings per share in 2015. Terms of the transaction were not disclosed. The transaction, which is subject to regulatory approvals and other customary closing conditions, is anticipated to close by the end of 2014.

Cell Marque, which designs, develops and manufactures antibody reagents and kits, is well-recognized in immunohistochemistry (IHC) for its high quality products and technical expertise, including validated, fit-for-purpose antibodies and IHC staining kits aimed at pathologists and clinicians focused on patient management. The company employs more than 90 people.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology